Researchers have identified a rare genetic variant tied to a 25-fold increase in lung cancer odds among people who have never smoked, according to a study published Thursday in the journal Science. A genetic variant is a small, inherited difference in DNA that some people carry and others do not. The discovery adds a concrete biological factor to a pattern that has puzzled scientists for years: nonsmokers now account for a growing share of lung cancer diagnoses.
What the research found
The short version is this. Scientists have known that never-smokers are increasingly showing up in lung cancer statistics, but pinning down the reasons has been difficult. Genetic factors and environmental exposures have both been studied as possible contributors. This work identifies one specific variant that, when present, is associated with sharply elevated odds of the disease.
The variant is rare overall. Within the United States, it is far more common among people in Southern Appalachia than elsewhere. That geographic concentration matters because it offers a concrete population in which to study risk, and it suggests that certain communities may face higher rates of never-smoker lung cancer than national figures would indicate.
Experts cited in the research noted the variant likely accounts for only a small portion of never-smoker lung cancer cases. Finding one piece of the puzzle does not close the question.
Why data scale made this possible
The investigators reached their findings by drawing on genetic data from 23andMe, the consumer genetics company. That dataset spans millions of people, which is what made detecting a rare variant statistically viable. Rare variants appear infrequently in any given sample, so a meaningful signal requires very large pools of genetic information. The study illustrates what population-scale health data can reveal when applied to carefully framed scientific questions.
What this could mean for screening
Never-smoker lung cancers carry distinct biological characteristics compared to tumors tied to smoking. This research adds evidence that those differences can stem from specific, identifiable risk factors. That has practical implications for how screening programs are designed. Today, smoking history is the primary risk indicator used to determine who gets screened. If certain genetic variants raise risk independently of smoking, criteria may eventually need to reflect that. Treatment strategies could also be affected, since tumors driven by specific genetic factors sometimes respond differently to therapies. The research does not immediately change clinical guidelines, but it gives scientists a defined target in a geography where follow-up work can now begin.